Visiongain Releases Drug Discovery Outsourcing Report 2014-2024

Visiongain has released a report detailing drug discovery information for 2014 to the year 2024. Interested parties can view the report to follow trends and discover segments with revenue potential. The report assesses data, prospects, and emerging opportunities. The guide helps evaluate pharmaceutical services, project sales, and forecast financial results. Visiongain provides independent business information for several industries including the pharmaceutical sector. The company provides custom reports as well. It is not associated with any organizations or advertisers.  

DRUG DISCOVERY OUTSOURCING: WORLD MARKET FORECAST 2014-2024

The 194-page report provides data visualization in the form of graphs, tables, and charts. It also offers interviews with two leading experts in the industry.  Dr. Mark Craighead, Director of Scientific Strategy at Redx Pharma and Dr. Barbara Slusher, Professor of Neurology, Psychiatry, and Neuroscience at Johns Hopkins University weigh in on future investments and sales.

The report forecasts revenues for four submarkets in the drug industry, chemical services, biological services, lead optimization, and lead identification and screening. It promises the competitive advantage in the submarkets with analysis of the competition and the forces driving opportunities.

Prospects for leading regions and countries are covered. Twelve national markets include the USA, Japan, Russia, and South Korea. Contract research organizations (CROs) can use the data to discover emerging countries like India and China. These emerging economies have competitive pricing and an educated workforce that study authors deem favorable to pharmaceutical outsourcing. The countries covered also have a commitment to technology, which is positive for drug research and manufacturing.

Visiongain estimates that the drug industry should earn 14.9 billion dollars in 2014. The report ties that revenue to 13 leading companies and provides profiles for these companies.  Readers can find a discussion of the company’s pipeline, financial prospects to 2014, and an assessment of recent development including mergers and acquisitions. Early-stage drug development is a prominent topic in the report. Readers find discussions on biologic drugs, changes in the R&D model, declining R&D budgets, target identification, intellectual property, private-public partnerships, and niche drug companies. 

Single user reports cost $3,000, while multi-user reports cost more. Interested parties can contact Visiongain for Bespoke Reports, customized reports that deliver specific information.

Source:

http://www.visiongain.com/Report/1180/Drug-Discovery-Outsourcing-World-Market-Forecast-2014-2024